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Despite months of mucosal virus exposure, the majority of breastfed infants born to HIV-infected mothers
do not become infected, raising the possibility that immune factors in milk inhibit mucosal transmission of
HIV. HIV Envelope (Env)-specific antibodies are present in the milk of HIV-infected mothers, but little is
known about their virus-specific functions. In this study, HIV Env-specific antibody binding, autologous and
heterologous virus neutralization, and antibody-dependent cell cytotoxicity (ADCC) responses were measured
in the milk and plasma of 41 HIV-infected lactating women. Although IgA is the predominant antibody isotype
in milk, HIV Env-specific IgG responses were higher in magnitude than HIV Env-specific IgA responses in
milk. The concentrations of anti-HIV gp120 IgG in milk and plasma were directly correlated (r  0.75; P <
0.0001), yet the response in milk was 2 logarithm units lower than in plasma. Similarly, heterologous virus
neutralization (r  0.39; P  0.010) and ADCC activity (r  0.64; P < 0.0001) in milk were directly correlated
with that in the systemic compartment but were 2 log units lower in magnitude. Autologous neutralization was
rarely detected in milk. Milk heterologous virus neutralization titers correlated with HIV gp120 Env-binding
IgG responses but not with IgA responses (r  0.71 and P < 0.0001, and r  0.17 and P  0.30). Moreover,
IgGs purified from milk and plasma had equal neutralizing potencies against a tier 1 virus (r  0.65; P <
0.0001), whereas only 1 out of 35 tested non-IgG milk fractions had detectable neutralization. These results
suggest that plasma-derived IgG antibodies mediate the majority of the low-level HIV neutralization and
ADCC activity in breast milk.
Breast milk transmission of human immunodeficiency virus
(HIV) accounts for almost half of the 400,000 pediatric HIV
infections occurring annually in resource-limited areas (68),
where replacement feeding is associated with high infant mor-
tality due to respiratory and diarrheal infections (1, 42). Anti-
retroviral interventions can significantly reduce the risk of HIV
transmission through breastfeeding (7, 58). However, little is
known about the effects of long-term antiretroviral prophylaxis
on infant development or maternal health, including the emer-
gence of antiretroviral-resistant strains of viruses in this set-
ting. Therefore, there is a need to develop alternative preven-
tive strategies, such as maternal or infant vaccination, that
would allow safe breastfeeding of infants born to HIV-infected
women.
Breast milk transmission of HIV has been correlated with
high milk levels of viral RNA, cell-associated viral DNA, and
mastitis (25, 51–52), but these associations do not fully explain
the low level of virus transmission through breastfeeding. In
the absence of antiretroviral prophylaxis, less than 10% of
infants born to HIV-infected women and breastfed during the
first 6 months of life become infected postnatally, despite daily
breast milk exposure (9). This low level of transmission sug-
gests that breast milk may contain protective antiviral factors.
Identifying these factors would provide important insights into
the type of immune responses required to protect against in-
fant HIV acquisition. As breast milk is a rich source of anti-
bodies, the potential antiviral activity of breast milk could be
mediated by adaptive humoral immune responses (20, 65).
Antibodies in milk are either transferred from plasma by tran-
sudation or locally produced by plasma cells that migrate to the
mammary gland from other mucosal sites, in particular, the
gut-associated lymphoid tissues (19). Antibodies against HIV
Env glycoproteins have been detected in the breast milk of
HIV-infected women (5, 31, 64). However, no quantitative
differences in milk HIV-specific antibody responses of trans-
mitting and nontransmitting mothers have been identified (5,
31). In simian immunodeficiency virus (SIV)-infected rhesus
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monkeys, although a lack of antibody response was associated
with early breast milk transmission, the levels of the SIV-
specific antibodies were similar in late transmitters and non-
transmitters (54). These findings indicate that the specificity
and the functionality of breast milk antibodies may be stronger
correlates of protection against infant virus acquisition than
the magnitude of the responses.
Systemic administration of neutralizing antibodies can pro-
tect neonatal rhesus monkeys against oral challenge with sim-
ian-human immunodeficiency virus (SHIV) (14, 53), indicating
a potential role for neutralizing antibodies in preventing ver-
tical transmission of HIV. Interestingly, previous studies have
reported an association between neutralization activity in ma-
ternal sera and protection against infant virus acquisition (3,
11, 56). Furthermore, viruses that are resistant to neutraliza-
tion by maternal plasma have been associated with HIV trans-
mission via breastfeeding (48). However, in a recent study,
there was no association between the magnitude and breadth
of heterologous virus neutralization in HIV-exposed infants at
birth and postnatal HIV acquisition (33). Thus, the role of
neutralizing antibodies in vertical transmission of HIV is un-
clear. Viruses isolated from the breast milk and plasma of
HIV-infected women have similar sensitivity to neutralization
by broadly HIV-neutralizing monoclonal antibodies (MAbs)
(55), but the ability of breast milk antibodies to neutralize
autologous and heterologous HIVs has not been studied.
Moreover, nonneutralizing antibodies, such as antibodies that
mediate antibody-dependent cellular cytoxicity (ADCC) re-
sponses, may contribute to better clinical outcome and lower
HIV/SIV load (2, 17, 41) and to the protection of vaccinated
rhesus macaques against SHIV challenge (71). However, little
is known about the ability of breast milk antibodies to mediate
this function. Therefore, it is necessary to further investigate
the neutralizing and nonneutralizing functions of breast milk
HIV Env-specific antibodies that could contribute to the pro-
tection of infants against HIV acquisition via breastfeeding.
Plasma and mucosal HIV Env-specific IgA antibody re-
sponses directed against gp140 and gp41 are detected in the
majority of individuals during acute HIV infection (72), yet in
studies of chronic infection, the magnitude and frequency of
HIV-specific IgA antibodies were low (30, 35). HIV-specific
mucosal IgA responses have been detected in the genital tracts
of highly exposed uninfected women, and these antibodies
were shown to neutralize HIV primary isolates (6, 8, 10, 27,
43). However, other studies have reported little or no evidence
of HIV-specific mucosal IgA responses in HIV-exposed unin-
fected subjects (12, 37). Furthermore, HIV-specific IgA anti-
bodies were rarely detected in the saliva of exposed uninfected
infants (13). In SIV-infected rhesus monkeys, SIV-specific IgA
antibodies isolated from milk had limited neutralization po-
tency compared to that of IgG (45). Breast milk secretory IgA
(sIgA) can inhibit virus transcytosis (5, 24), but this function
does not appear to correlate with protection (5). Thus, the
antiviral functions of breast milk IgA need to be further inves-
tigated in order to elucidate the potential roles of mucosal IgA
in protection against mucosal HIV transmission.
In this study, HIV Env-specific antibody responses were
measured in breast milk and plasma from 41 HIV-infected
lactating women from Blantyre, Malawi. The magnitude and
breadth of the HIV Env-binding IgG and IgA responses, the
autologous and heterologous neutralization responses, and the
ADCC activity were characterized in the systemic and breast
milk compartments. Further, the IgG and IgA fractions of
breast milk and plasma were isolated and assessed for heter-
ologous neutralization, providing insight into the functional
role of each HIV Env-specific antibody isotype in milk.
MATERIALS AND METHODS
Study population. Pregnant women testing HIV positive by a rapid antibody
test were recruited from two rural health clinics outside Blantyre, Malawi, as part
of the CHAVI 009 protocol. Women were enrolled at delivery if HIV infection
was confirmed by HIV RNA and breastfeeding was initiated. All mothers and
infants in this study received single-dose nevirapine at delivery. Maternal plasma
and breast milk samples from 41 women who remained off antiretroviral therapy
during lactation (except nevirapine at delivery) were included. The breast milk
samples were centrifuged at low speed and separated into a breast milk cell layer,
supernatant, and a fat layer. The breast milk supernatant was frozen at 20°C
until it was used. The median CD4 count was 360 (range, 80 to 833). Samples
were collected at 4 to 6 weeks, at 3 months, and then every 3 months after
delivery until the cessation of breastfeeding or the infant reached 18 months of
age. Additionally, breast milk and plasma samples collected from nine lactating
uninfected women recruited from the same rural Malawian health clinics and
four uninfected women recruited in Boston, MA, were used as negative controls.
This study was approved by the College of Medicine Research and Ethics Com-
mittee in Malawi and institutional review boards at each of the participating
institutions where samples were received or processed for end user analysis.
HIV plasma and breast milk virus load. Viral loads in breast milk and plasma
were measured using the Roche Cobas Ampliprep/Cobas TaqMan 48 for HIV-1
load assay. The breast milk supernatant was diluted 1:5 in phosphate-buffered
saline (PBS) prior to analysis, the optimal dilution for the most accurate quan-
titation of virus RNA based on preliminary assays with milk containing a known
quantity of virus. The detection limit of this assay for breast milk is 240 RNA
copies/ml and 48 RNA copies/ml for plasma. Viral RNA was detected in 17 of 34
tested breast milk samples and in 31 of 34 plasma samples. If virus RNA was
detected in the sample but below the minimum for quantitation, a value of half
the minimum for detection was assigned. The median virus load in breast milk
was 770 RNA copies/ml (range, not detectable to 155,000 RNA copies/ml) and
5,340 RNA copies/ml in plasma (range, not detectable to 202,000 RNA copies/
ml). The laboratory performing these assays was enrolled in the National Insti-
tute of Allergy and Infectious Diseases Division of AIDS Virology Quality
Assessment program and certified for HIV load determinations.
HIV env gene single-genome amplification and cloning. Plasma aliquots con-
taining approximately 10,000 RNA copies were extracted using a QIAamp viral
RNA minikit (Qiagen). For plasma samples with low viral loads (10,000 RNA
copies/ml) and all breast milk supernatants, aliquots of 1 ml were concentrated
10 times by centrifugation at 23,600  g for 1 h at 4°C (final volume, 100 l)
before RNA extraction. Depending on the virus RNA load, between 200 and
10,000 RNA copies were reverse transcribed. Single-stranded cDNA was syn-
thesized using the SuperScript III protocol according to the manufacturer’s
instructions (Invitrogen Life Technologies) and either used immediately for PCR
or stored frozen at 80°C. Full-length env genes were PCR amplified by single-
genome amplification methods as previously described (28). Briefly, cDNA was
titrated by endpoint dilution (undiluted to 1:40 dilution for breast milk cDNA)
in 96-well PCR plates to a concentration that yielded no more than 30% PCR-
positive wells and conformed to a Poisson distribution of a single template per
reaction. The reaction mixture for the first round of PCR (total volume, 20 l)
consisted of 1 High Fidelity platinum PCR buffer, 2 mM MgSO4, 0.2 mM each
deoxynucleoside triphosphate, 0.2 M primers Vif1 (5-GGGTTTATTACAGG
GACAGCAGAG-3; nt 4900 to 4923) and OFM19 (5-GCACTCAAGGCAA
GCTTTATTGAGGCTTA-3), and 0.025 U/l platinum Taq High Fidelity poly-
merase (Invitrogen). The following PCR conditions were used: 94°C for 2 min,
followed by 35 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 4 min, with a
final extension of 68°C for 10 min. The second-round PCR was carried out using
2 l of the first-round product and 0.2 M primers EnvA (5-GGCTTAGGCA
TCTCCTATGGCAGGAAGAA-3; nt 5954 to 5982) and EnvN (5-CTGCCA
ATCAGGGAAGTAGCCTTGTGT-3; nt 9145 to 9171) with the same PCR
mixture as the first round. The conditions were 94°C for 2 min, followed by 45
cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 4 min, with a final extension
at 68°C for 10 min. The amplicons were sized on precast 1% agarose E-gel 96
(Invitrogen Life Technologies) and gel purified according to the manufacturer’s
instructions (Qiagen). Amplicons derived from cDNA dilutions yielding less than
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30% PCR positivity were DNA sequenced using BigDye Terminator v.3.1 chem-
istry and the protocols recommended by the manufacturer (Applied Biosystems).
The sequences were determined by using an ABI 3730xl DNA analyzer (Applied
Biosystems) and edited by using the Sequencher program, version 4.9 (Gene
Codes). The purified amplicons were ligated into pcDNA3.1 Directional Topo
vectors (Invitrogen) and used to transform TOP10 Escherichia coli cells accord-
ing to the manufacturer’s instructions. Cultures were grown at 30°C, and selected
colonies were screened by miniprep and restriction digested with XhoI and
BamHI (New England BioLabs). Plasmids with fragments of the correct size
after restriction digestion were sequenced to confirm sequence identity to the
original env amplicon. Confirmed env clones were grown in large culture at 30°C.
Plasmids were prepared by Megaprep (Qiagen) and resequenced to again con-
firm sequence identity to the original env amplicon.
Pseudovirus preparation. Env pseudoviruses were prepared by transfection in
293T cells with 4 g of env plasmid DNA and 8 g of env-deficient HIV plasmid
DNA using the FuGene 6 transfection reagent (Roche Diagnostics). Two days
after transfection, the culture supernatant containing pseudoviruses was har-
vested, filtered, aliquoted, and stored at 80°C. An aliquot of frozen pseudovirus
was used to measure the infectivity in TZM-bl cells. Serial 5-fold dilutions of
pseudovirus were distributed in quadruplicate to 96-well flat-bottom plates (Co-
star) in a total volume of 100 l per well. Then, freshly trypsinized TZM-bl cells
were added (10,000 cells/well in Dulbecco’s modified Eagle’s medium [DMEM]-
10% fetal bovine serum [FBS] containing HEPES and 10 g/ml of DEAE-
dextran). After 48 h of incubation at 37°C, 100 l of cells/well was transferred to
a 96-well black solid plate (Costar), and the luminescence was measured using
the Britelite Plus luminescence reporter gene assay system (Perkin-Elmer Life
Sciences). Wells producing relative luminescence units (RLU) 3 times back-
ground were scored as positive, and the TCID50 was calculated by the method of
Reed and Muench, as previously described (26).
Quantification of total and HIV Env-specific IgG and IgA antibodies in breast
milk and plasma. The concentrations of total IgA and IgG antibodies in plasma
and milk were measured by commercial enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (Immunology Consultants
Laboratory, Inc.). Levels of HIV Env-specific IgA and IgG were determined with
a customized HIV-1 binding antibody multiplex assay as previously described
(61) with some modifications. Briefly, a total of 5  106 carboxylated fluorescent
beads (Luminex Corp.) were covalently coupled to 25 g of purified HIV antigen
and incubated with patient samples at various dilutions. HIV-specific antibody
isotypes were detected with phycoerythrin (PE)-conjugated goat anti-human IgA
(Jackson ImmunoResearch) or PE-conjugated mouse anti-human IgG (South-
ern Biotech). The beads were then washed and acquired on a Bio-Plex instru-
ment (Bio-Rad). The results were expressed as mean fluorescence intensity
(MFI). For enhanced detection of IgA antibodies, IgG was removed using
protein G columns, as described below. The positive controls in each assay
included purified IgG and IgA proteins (Sigma-Aldrich), HIVIG (Quality Bio-
logical), and a constant HIV-positive serum titration. Normal human plasma was
utilized as a negative control, and unconjugated beads were used to control for
nonspecific binding of sample to the beads. HIV-1 Env-specific antibodies were
captured using the following proteins: a clade C consensus Env gp120 con-
structed from alignments of full-length subtype C Env sequences available in
2001 in the Los Alamos HIV sequence database (29) (ConC gp120, provided by
Lynn Morris and Elin Gray, National Institute of Communicable Diseases,
Johannesburg, South Africa); an artificial multiclade consensus Env gp120 de-
scribed previously (18) (Con6 gp120); a multiclade gp140 consensus Env con-
structed from alignments of full-length subtype C Env sequences available in
2002 in the Los Alamos HIV sequence database with deletions in the gp41
cleavage site, fusion domain, and immunodominant region (ConS gp140); a clade
C consensus Env gp140 with deletions in the gp41 cleavage site and fusion
domain (ConC gp140); a previously described (69) gp140 Env from a clade C
primary isolate (DU123 gp140); a gp140 trimer from a transmitted/founder virus
obtained from a single-genome amplified sequence by Ronald Swanstrom, Uni-
versity of North Carolina, Chapel Hill, NC (1086C gp140); and a recombinant
gp41 Env (Immunodiagnostics). Con6 gp120, ConS gp140, ConC gp140, 1086C
gp140, and DU123 gp140 envelope proteins were all provided by Hua-Xin Liao
and Barton Haynes, Duke Human Vaccine Institute, Durham, NC. Antibody
concentrations were determined by applying standard curves generated by titrat-
ing HIV Env-specific MAbs in a 4PL curve analysis: 2G12 IgG (62), provided by
Herman Katinger, Polymune Scientific, Vienna, Austria (for Con6 gp120 IgG
and ConS gp140 IgG), b12 IgA (34), provided by Anne Hessell and Dennis
Burton, Scripps Research Institute (for Con6 gp120 IgA and ConS gp140 IgA);
and 2F5 IgG and IgA (40), obtained from Polymune (for gp41 IgG and IgA).
Breast milk delipidization. To reduce breast milk cell toxicity, the samples
were delipidized prior to functional assay testing. Milk samples were centrifuged
at 25,000  g at 4°C for 30 min and then filtered using spin X filter tubes (Fisher).
The efficiency of the procedure was tested by incubating serial dilutions of
nondelipidized and corresponding delipidized milk samples with TZM-bl cells in
the absence of virus for 48 h and measuring luminescence. Cell toxicity was
observed by microscopy in wells containing the three lowest dilutions of nonde-
lipidized milk, and the MFI in these wells was lower than in control wells. No
toxicity was observed based on microscopy or MFI deflection with delipidized
samples. To ensure that the procedure did not affect antibody function, a neg-
ative breast milk sample was spiked with either b12 IgG or HIVIG prior to
delipidization and assayed for neutralization of a tier 1 virus. The delipidization
procedure did not affect the neutralization potency of b12 or HIVIG.
IgG and non-IgG fraction purification. IgG was purified from plasma and
breast milk using protein G resin prepacked into 96-well depletion plates (GE
Healthcare). Plasma samples were clarified by centrifugation at 10,000  g for 10
min and diluted 2-fold with PBS (pH 7.5). A total of 200 l of diluted plasma or
delipidized breast milk was added to each well, and the plates were incubated at
room temperature, with shaking, for 1 h. Unbound fractions were removed by
centrifugation at 1,200  g for 3 min. The wells were then washed 3 times with
200 l of Tris-buffered saline (TBS). IgG bound to the resin was eluted with
2.5% glacial acetic acid and immediately neutralized with 120 l of 1 M Tris-
HCl, pH 9.0. The unbound fractions of milk were then run over Protein L Spin
Columns according to the protocol (Pierce) to purify the non-IgG antibody
fraction. The eluted IgG and non-IgG fractions were concentrated using Amicon
Ultra centrifugal filters with a 30,000-Da cutoff (Millipore). The protein concen-
tration was determined by spectrophotometry at A280 using a NanoDrop 1000
spectrophotometer (Thermo Fisher Scientific). Extinction coefficients of 1.36
(the extinction coefficient for monomeric IgG) and 1.26 (the extinction coeffi-
cient of sIgA) (44) were used to calculate the antibody concentrations for the
IgG and non-IgG fractions, respectively. The purities of the IgG and non-IgG
fractions were tested in a subset of samples by ELISA. No IgA was detected in
the IgG fraction, and the non-IgG fraction contained 2% IgG. The presence of
sIgA in the non-IgG fraction was confirmed by commercial ELISA (Antibodies-
Online Inc.).
IgA purification. IgA was purified from the 6 breast milk-plasma pairs with the
highest milk HIV Env-specific IgA magnitudes and breadths by binding to
peptide M resin (Invitrogen). Briefly, peptide M gel slurry (250 l) was loaded
into spin columns (Millipore); then, IgG-depleted milk preparations were loaded
onto the columns and incubated with rocking at room temperature for 45 min.
After incubation, the columns were washed and the flowthrough fractions were
collected. The bound antibodies were then eluted with elution buffer (Thermo
Scientific) in small fractions and neutralized immediately with neutralization
buffer (Thermo Scientific). The columns were subsequently regenerated by wash-
ing with regeneration buffer and used for another round of purification of the
flowthrough to increase the yield. Finally, the eluted fractions from the two
consecutive purification processes were combined for each sample, buffer ex-
changed with PBS, and concentrated using Amicon Ultra-4 filters. The protein
concentration was determined by spectrophotometry at A280 using a NanoDrop
1000 spectrophotometer (Thermo Fisher Scientific). The purified IgA fractions
were tested in the binding antibody multiplex assay to confirm the presence of
HIV-specific IgA and the efficient removal of IgG.
Autologous and heterologous virus neutralization. Autologous and heterolo-
gous neutralization assays were performed in TZM-bl reporter cells. For autol-
ogous virus neutralization assays, five to nine breast milk- and plasma Env-
pseudotyped viruses from each of five HIV-infected women were tested. The
autologous Env clones were sequenced and cloned from milk and plasma col-
lected 4 to 6 weeks postdelivery. Plasma and milk samples collected from that
time point and all subsequent available time points were assayed in these five
subjects. For heterologous virus neutralization assays, one clade C tier 1 virus
(HIV MW965.26) and two clade C tier 2 viruses (HIV DU422.1 and HIV
CAP45.200.G3) were used. Breast milk and plasma samples from all 41 women
collected 4 to 6 weeks after delivery were assayed. Purified milk IgG, non-IgG,
and IgA fractions were subsequently tested against the tier 1 virus. Prior to
neutralization assessment, the plasma samples were heat inactivated at 56°C for
1 h and the breast milk samples were delipidized and concentrated 4 times using
Amicon Ultra centrifugal filters with a 100,000 cutoff. Neutralization was mea-
sured by the reduction in luciferase reporter gene expression after a single round
of infection in TZM-bl cells, as previously described (32). Briefly, diluted virus
preparations (a predetermined dilution yielding RLU at least 10 times above the
cell control background) were incubated with 3-fold serial dilutions of plasma,
concentrated milk supernatant, or purified immunoglobulin-milk preparations in
duplicate for 1 h at 37°C in 96-well flat-bottom culture plates. TZM-bl cells were
then added (1  104/well in a 100-l volume) in 10% FBS-DMEM growth
medium containing DEAE-dextran (Sigma) at a final concentration of 10 g/ml.
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Assay controls included replicate wells of TZM-bl cells alone (cell control) and
TZM-bl cells with virus (virus control). In addition, negative-control assays were
performed using a murine retrovirus (simian virus amphotropic murine leukemia
virus [SVA.MLV]) Following 48 h of incubation at 37°C, luminescence was
measured using the Britelite Plus luminescence reporter gene assay system (Per-
kin-Elmer Life Sciences). The 50% inhibitory dose (ID50) titer was calculated as
the plasma or milk dilution that caused a 50% reduction in RLU compared to the
virus control wells after subtraction of cell control RLU. The 4 concentration
of breast milk was taken into account in calculating the breast milk dilution. A
dilution of sample was considered positive for neutralization when the ID50 was
higher than 3 standard deviations above the median of the negative controls and
3 times above the SVA.MLV control. The 50% inhibitory concentration (IC50)
titer was calculated as the purified Ig concentration that caused a 50% reduction
in RLU.
ADCC. ADCC activities in breast milk and plasma were measured using an
adapted GranToxiLux (OncoImmunin, Inc.) protocol (45a). The assay is based
on the cleavage of a cell-permeable green fluorogenic peptide substrate by the
serine-protease granzyme B (GzB) within target cells. GzB is synthesized and
stored in cytotoxic cells in an inactive form. When effector cells recognize target
cells through antibody (Ab)-Fc-receptor interactions, their granule content, in-
cluding GzB, is released into target cells. In this assay, GzB cleaves its fluoro-
genic substrate within the target cells, thereby generating a green fluorescent
signal that can be quantified by flow cytometry. CEM.NKRCCR5 target cells were
coated with recombinant HIV-1 DU422.1 gp120 to saturation, counted, washed,
and resuspended at 1  106 cells/ml in complete medium (RPMI 1640 with 10%
FBS). The target cells were labeled with a red fluorescent maker and a viability
marker. Viable cells were counted with a Guava PCA system (Millipore) and
then adjusted to a concentration of 0.4  106 cells/ml. Cryopreserved peripheral
blood mononuclear cells (PBMCs) were used as effector cells. The PBMCs were
thawed and rested overnight at 2  106 cells/ml in complete medium and then
counted and resuspended at 12  106 viable cells/ml. Effector and target cell
suspensions (25 l of each) were dispensed into each well of a 96-well V-bottom
plate and incubated with 75 l of GzB substrate at room temperature for 5 min.
Diluted milk and plasma samples (25 l) were then added. The final effector-
to-target ratio was 30:1, and the final GzB substrate concentration was 0.25.
After 15 min of incubation at room temperature, the plates were centrifuged for
1 min at 300  g, incubated for 1 h at 37°C and 5% CO2, and then washed twice
with PBS containing 1% FBS. The cells were then resuspended in a final volume
of 225 l of PBS-1% FBS and placed at 4°C until they were analyzed. A
minimum of 2,500 events representing viable target cells were acquired within
5 h. The maximal cytotoxic potency was defined as the maximal proportion of
gp120-coated target cells positive for GzB activity after incubation with 5-fold
serial antibody dilutions and effector cells. The results were expressed as percent
GzB activity, defined as the percentage of GzB-positive cells out of the total
viable target population. For final results, the background (percent GzB activity
in wells containing effector and target cell populations and no test samples) was
subtracted. The ADCC-mediating antibody titer was defined as the reciprocal of
the lowest dilution indicating a positive GzB response (8.1% GzB activity) after
background subtraction.
Statistical analysis. The paired nonparametric Wilcoxon signed rank test was
used to compare the magnitudes of HIV Env-specific IgG and IgA antibodies in
milk and plasma. The Spearman correlation coefficient was used to determine
the correlation between the binding, neutralizing, and ADCC responses in milk
and plasma. This test was also used to determine the correlation of milk neu-
tralizing and ADCC responses with HIV-specific IgG and IgA responses and the
correlation between the viral load and antibody responses. The lowest tested
dilution of plasma/milk was used to compute undetectable levels of functional
antibodies. Fisher’s exact test was used to compare the proportions of women
with detectable responses in plasma and milk. All statistical tests were performed
with Graphpad (La Jolla, CA) Prism 5.
Nucleotide sequence accession numbers. All env sequences determined in this
study were deposited in GenBank (accession numbers HM070449 to HM070824
and HQ595810 to HM596189).
RESULTS
IgA is the predominant antibody isotype in milk, yet the HIV
Env-specific humoral response in milk is primarily IgG iso-
type. We first sought to assess the relationship between the
magnitude of the HIV-specific humoral immune responses and
the total IgG and IgA content in breast milk of HIV-infected
lactating women. To examine the IgG and IgA content of
breast milk compared to that in plasma, we quantified total
IgG and IgA in plasma and milk samples collected 4 to 6 weeks
after delivery from chronically HIV-1-infected women from
Blantyre, Malawi (Fig. 1). The median level of IgG was 18.7
mg/ml (range, 5.1 to 62 mg/ml) in plasma and 0.08 mg/ml
(range, 0.02 to 0.4 mg/ml) in milk (Fig. 1). Thus, plasma con-
tains 2 log units more IgG than milk (P  0.0001). The total
IgA content was 0.5 to 1 log unit higher in plasma than in milk
(median, 3.9 mg/ml versus 0.71 mg/ml; P  0.0001); however,
it is possible that a portion of the milk IgA could be associated
with the fatty fraction of the milk that is removed with the
delipidization procedure. Consistent with previous character-
izations of antibody isotypes in milk (60), breast milk samples
contained 0.5 to 1 log unit more total IgA than IgG (P 
0.0001), whereas plasma samples contained approximately 1
log unit less IgA than IgG (P  0.0001) (Fig. 1).
The magnitudes and breadths of the HIV Env-binding IgG
and IgA binding responses in milk were then assessed using a
panel of HIV Env antigens, including two consensus gp140
proteins (ConS gp140 and ConC gp140), one gp140 Env pro-
tein from a clade C primary isolate (DU123 gp140), two con-
sensus gp120 proteins (Con6 gp120 and ConC gp120), a con-
sensus gp41 Env protein, and a transmitted/founder gp140 Env
trimer (1086c gp140). To ensure that high-affinity IgG did not
interfere with IgA binding, samples were depleted of IgG prior
to measurement of HIV-specific IgA. HIV Env-specific IgG
responses against all of the above-mentioned Env antigens
were detected in plasma and breast milk of all subjects (41/41),
but the seroprevalence of IgA responses to gp120 proteins was
higher in plasma samples than in milk samples (Table 1).
Similarly, IgA antibodies against gp41 were detected in 41 out
of 41 plasma samples and in only 4 out of 41 milk samples (P 
0.0001). IgA responses against gp140 proteins were detected in
the plasma and milk of most subjects, but as with the other
antigens, the frequency of positive IgA gp140 responses was
significantly higher in plasma than in milk (Table 1). Moreover,
IgA antibodies to the transmitted/founder Env trimer were
detected in 40 out of 41 plasma and in 30 out of 41 breast milk
samples (P  0.003). This difference in the seroprevalence of
HIV Env-specific IgA responses between plasma and milk
might indicate partial compartmentalization of the milk IgA
response.
FIG. 1. Total IgG and IgA are lower in breast milk than in plasma.
Shown is the total IgG and IgA contents in plasma and breast milk of
41 HIV-infected lactating women. In Fig. 1 to Fig. 6, the lines in the
panels represent the medians.
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The levels of gp120, gp140, and gp41 IgG and IgA antibody
responses in milk did not correlate with the milk viral load
(IgG, r values between 0.07 and 0.24 and P values between 0.15
and 0.56; IgA, r values between 0.10 and 0.24 and P values
between 0.19 and 0.79). However, there was a strong correla-
tion between the levels of IgG and IgA antibodies to interclade
and clade C consensus gp120 proteins (r  0.69 to 0.78 and P 
0.0001 for all) and between the levels of interclade and clade C
(either consensus or primary isolate) antibodies to gp140 pro-
teins (r  0.56 to 0.93 and P  0.0001 for all) in both plasma
and milk. There was also a very strong correlation between
binding antibodies to the consensus clade C and the clade C
primary isolate DU123 gp140 proteins (r  0.84 to 0.97 and
P  0.0001) (data not shown), indicating that the IgG and IgA
binding antibody responses in the plasma and milk may be
mainly directed against conserved epitopes.
The concentrations of antibodies directed against gp140
(ConS), gp120 (Con6), and gp41 in plasma and milk were
estimated by assaying the plasma and milk HIV Env binding
compared to that of known concentrations of antigen-matched
HIV Env-specific MAbs. After plotting the MFI of each sam-
ple on the MAb standard curve, the results were expressed in
ng/ml equivalents (eq). When detected in plasma and milk
samples, the magnitudes of the HIV Env-specific IgG binding
responses were higher than those of the HIV Env-specific IgA
binding responses for all antigens in both compartments, ex-
cept for gp41 in milk (gp140, P  0.0001 in plasma and P 
0.0003 in milk; gp120, P  0.0001 in plasma and milk; and
gp41, P  0.0001 in plasma and P  0.62 in milk) (Fig. 2A to
C). Thus, the HIV Env-specific IgG response appears to be pre-
dominant in both the breast milk and systemic compartments.
This observation in milk is surprising, as breast milk contains
approximately 1 log unit more total IgA than total IgG antibodies
(Fig. 1). However, these results are in agreement with previous
reports of an IgG-biased HIV Env-specific response in breast
milk and other mucosal compartments (35, 49, 64).
As plasma has a higher total IgG and IgA content than milk,
we expected the concentrations of HIV Env-binding antibodies
to be higher in plasma than in milk. As predicted, the concen-
trations of IgG antibodies against all Env antigens were higher
in plasma than in milk (median plasma versus milk Env anti-
gen-specific antibody concentrations: gp140, 2.6  106 versus
1.1  104 2G12 IgG ng/ml eq; gp120, 6.6  105 versus 1.8  103
2G12 IgG ng/ml eq; and gp41, 7.8  106 versus 2.1  104 2F5
IgG ng/ml eq; P  0.0001 for all) (Fig. 2A to C). When
detectable, there was no difference in the concentrations of
IgA antibodies in plasma and milk against gp120 (median
concentration, 0.14  103 versus 0.29  103 b12 IgA ng/ml eq;
P  0.33) or gp41 (median concentration, 5.0  103 versus
5.4  103 2F5 IgA ng/ml eq; P  0.87). However, the concen-
tration of IgA antibodies to gp140 was significantly higher in
plasma than in milk (median concentration, 0.23  103 versus
0.16  103 b12 IgA ng/ml eq; P  0.0075). Interestingly, there
was a strong correlation between the concentration of HIV
Env-binding IgG responses against gp120 and gp140 antigens
in the two compartments (gp140, r  0.71 and P  0.0001;
gp120, r  0.75 and P  0.0001) (Fig. 2D and E). However,
these correlations may be driven by the subset of women with
high Env-specific IgG levels in both milk and plasma. There
was also a statistically significant trend toward a correlation of
the concentrations of IgG antibodies against gp41 in milk and
plasma (r  0.45; P  0.0027) (Fig. 2F). In contrast, the
concentrations of HIV Env-binding IgA responses did not
correlate between plasma and milk (gp140, r  0.26 and P 
0.16; gp120, r  0.10 and P  0.72) (Fig. 2G and H). These
results suggest that the majority of the HIV-specific IgG anti-
bodies in milk originate from plasma and further indicate that
milk and plasma HIV Env-specific IgA responses are at least
partially compartmentalized.
Breast milk neutralizes heterologous HIV virions with lower
potency than plasma. We then investigated the ability of the
HIV Env-specific antibody responses in breast milk to neutral-
ize the virus, as virus neutralization by breast milk is a possible
mechanism for blocking HIV infection in the infant oral/gas-
trointestinal tract. The abilities of plasma and milk samples to
neutralize heterologous viruses were measured against one tier
1 clade C (HIV MW965.26) and two tier 2 clade C (HIV
DU422.1 and HIV CAP 45.2.00.G3) viruses. All of the chron-
ically HIV-infected mothers had potent neutralizing activity in
plasma against the tier 1 virus, with ID50 titers ranging from
583 to 116,990 (median ID50 titer, 20,583). This virus was
neutralized by a significantly lower frequency of milk samples
(23/41 subjects; P  0.0001) (Fig. 3A). Furthermore, the tier 1
virus neutralization titer of milk was severalfold lower than
that of plasma (median ID50 titer, 103; range, 37 to 549). A
positive correlation was observed between tier 1 virus neutral-
ization titers in milk and plasma (r  0.39; P  0.01) (Fig. 3D),
suggesting that milk neutralization may be partially mediated
by antibodies that cross from the systemic circulation into the
breast milk. There was no correlation between milk tier 1
neutralization and the milk viral load (r  0.27; P  0.14) (data
not shown). Neutralization of the tier 2 viruses was detected in
plasma of 56 to 61% of the subjects (23/41 for HIV
CAP45.2.00.G3 and 25/41 for HIV DU422.1) (Fig. 3B and C).
TABLE 1. Seroprevalence of HIV Env-binding IgG and IgA in plasma and milk
HIV Env
antigen
IgG prevalence % (no.)	 IgA prevalence % (no.)	 P value (Fisher’s exact test),
plasma vs. milk IgAPlasma Milk Plasma Milk
ConS gp140 100 (41/41) 100 (41/41) 97.5 (40/41) 71 (29/41) 0.0015
ConC gp140 100 (41/41) 100 (41/41) 95 (39/41) 68 (28/41) 0.0032
DU123 gp140 100 (41/41) 100 (41/41) 90 (37/41) 71 (29/41) 0.048
Con6 gp120 100 (41/41) 100 (41/41) 76 (31/41) 39 (16/41) 0.0016
ConC gp120 100 (41/41) 100 (41/41) 73 (30/41) 27 (11/41) 0.0001
gp41 100 (41/41) 100 (41/41) 100 (41/41) 10 (4/41) 0.0001
1086c gp140 100 (41/41) 100 (41/41) 97.5 (40/41) 73 (30/41) 0.0033
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In contrast, only 22% (9/41) of the HIV-infected lactating
women had detectable neutralization of HIV CAP45.2.00.G3
in milk (P  0.0030), and none of the subjects’ milk neutralized
HIV DU422.1 (P  0.0001). This low level and frequency of
neutralization in milk against both tier 1 and tier 2 HIV is prob-
ably related to the small amount of HIV Env-specific antibodies
in milk compared to that in plasma (Fig. 2). Although it is likely
that a portion of immunoglobulin was lost during the delipidiza-
tion procedure, the procedure did not interfere with neutraliza-
tion in control assays. As most circulating HIV strains display a
tier 2 neutralization phenotype (57), our findings may indicate
that the amount of HIV Env-specific antibodies in breast milk is
not sufficient for autologous virus neutralization.
Plasma and milk IgG antibodies have equal neutralization
potencies. To determine if the weak neutralization potency of
milk was due to the low concentration of HIV Env-specific
antibodies, we isolated IgG from milk and plasma of HIV-
infected lactating women. We measured the neutralization po-
tencies of the purified milk and plasma IgG fractions against
the tier 1 HIV MW965.26 (Fig. 4A). Neutralizing activity was
detected in the plasma IgG fractions of all HIV-infected lac-
tating women (41/41) and in the milk IgG fractions of 95% of
the subjects (39/41). Notably, there was no difference in the
median IC50s of the plasma (1.55 g/ml; range, 0.24 to 40.75
g/ml) and milk (1.13 g/ml; range, 0.17 to 36.94 g/ml; P 
0.38) IgG fractions. Moreover, there was a strong correlation
between milk and plasma IgG IC50s (r  0.65; P  0.0001)
(Fig. 4B). Thus, the IgG fractions of milk and plasma have the
same capacity to neutralize HIV, after adjusting for their an-
tibody contents.
Limited neutralization potency of the non-IgG fractions of
breast milk. The non-IgG fraction of breast milk was purified
from 35 of the breast milk samples by binding of the IgG-
depleted fraction to protein L columns. The fractions were
then tested for neutralization of the tier 1 virus. Neutralizing
activity was detected in 1 out of the 35 non-IgG milk fractions
(subject 1209; IC50, 19.01 g/ml). As protein L binds to kappa
light chains, our preparations could contain both IgA and IgM
antibodies. Therefore, we specifically purified IgA from the six
milk samples with the highest HIV Env-specific IgA breadths
and magnitudes and from their corresponding plasma by af-
finity binding to peptide M, which binds monomeric and di-
FIG. 2. The HIV Env-binding antibody response in breast milk is predominantly IgG isotype. (A) Anti-gp140 IgG and IgA concentrations in
plasma and corresponding milk of 40 HIV-infected women. (B) Anti-gp120 IgG and IgA concentrations in plasma and corresponding milk of 40
HIV-infected women. (C) Anti-gp41 IgG and IgA concentrations in plasma and milk. (D to H) There is strong correlation between anti-gp140,
anti-gp120, and anti-gp41 IgG concentrations, but not between anti-gp140 or anti-gp120 IgA concentrations, in plasma and milk.
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meric human IgA1 and IgA2. Testing of the IgA fractions of
breast milk indicated that IgA from subject 1209 was respon-
sible for the neutralization detected in the non-IgG milk frac-
tion (Table 2). In addition, the plasma IgA fraction from 1209
also neutralized the tier 1 virus. The plasma, but not the milk,
IgA fraction of subject 0605 also neutralized (IC50, 23.76 g/
ml). Interestingly, although comparable levels of HIV Env-
specific IgA (Table 2) were detected in other plasma and
breast milk samples tested for IgA neutralization, no neutral-
izing activity was detected. In contrast, the IgG fractions from
all six samples neutralized the tier 1 virus (IC50 range, 0.49 to
20.47 g/ml and 0.6 to 12.5 g/ml for plasma and milk, respec-
tively) (Table 2), demonstrating that potent IgA-mediated
neutralization of HIV is not frequent in breast milk.
Lack of detectable autologous virus neutralization in breast
milk of HIV-infected lactating women. The ability of breast
milk to neutralize milk and plasma autologous viruses was
measured over the period of lactation (6 to 12 months) in five
FIG. 3. Breast milk neutralizes heterologous HIV-1 with low potency, yet the neutralizing titer in milk is correlated to that in plasma. (A to
C) Neutralization titers of 41 plasma and corresponding breast milk samples against HIV MW965.26, a clade C tier 1 virus (A); HIV
CAP45.2.00.G3, a clade C tier 2 virus (B); and HIV DU422.1, a clade C tier 2 virus (C). Only samples that had a neutralization titer greater than
3 standard deviations above the mean of three HIV-negative plasma samples or six HIV-negative milk samples are presented. (D) A direct
correlation was observed between the neutralization titers of plasma and corresponding milk samples for the tier 1 virus.
FIG. 4. Plasma and breast milk IgGs of HIV-infected women neutralize HIV-1 with the same potency. (A) IC50s of plasma and milk IgG
fractions from 41 HIV-infected women against a tier 1 virus (HIV MW965.26) are not statistically different (P  0.36). (B) Direct correlation of
the IC50s of paired plasma and milk IgG fractions.
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untreated, HIV-infected, lactating women. The autologous vi-
rus neutralization of plasma and milk was assessed against five
to nine autologous Env-pseudotyped viruses amplified from
plasma or milk collected at week 4 following delivery. Nonspe-
cific neutralization was assessed in plasma and milk from un-
infected, lactating women against a control murine retrovirus
(SVA.MLV). In general, there was no difference in the abilities
of plasma samples to neutralize autologous plasma versus milk
viruses (Table 3). However, patient 4403 plasma neutralized all
the milk but none of the plasma viruses. Weak neutralization
titers were detected in the plasma of each woman at most visits,
with ID50 titers generally lower than 100 (Table 3). However,
patient 3902 showed moderate to high neutralization potency
at 9 months, with ID50s as high as 463. These results confirm
that milk and plasma virus Envs have comparable neutraliza-
tion sensitivities, as previously indicated by assessment of milk
and plasma virus Env neutralization sensitivity using broadly
neutralizing MAbs (55).
The majority of the breast milk samples from uninfected
lactating women displayed low levels of nonspecific HIV-neu-
tralizing activity. This activity could be mediated by previously
reported antiviral proteins in the milk, such as lactoferrin or
secretory leukocyte protease inhibitor (20, 66). To account for
the nonspecific activity, only samples with ID50s higher than 3
standard deviations above the mean ID50 of the uninfected
milk samples were considered positive. Based on this criterion,
only one milk sample neutralized a milk virus (4707.BMF8)
(Table 3). Thus, milk from HIV-infected lactating women does
not potently neutralize autologous virus.
Breast milk antibodies mediate ADCC with a lower titer
than but potency equal to that in plasma. We next determined
the ability of milk antibodies to mediate another important
virus-specific effector function, ADCC (Fig. 5). Target cells
were coated with recombinant clade C gp120 (HIV DU422.1),
and antibody-mediated cytotoxicity was measured by the re-
lease of GzB from NK cell granules. ADCC activity was de-
tected in the milk of all subjects, with titers ranging from 19 to
3,272 (median titer, 385), but this response was severalfold
lower than that in plasma (median, 81,132; range, 12,644 to
912,152) (P  0.0001) (Fig. 5A). Nevertheless, similar to the
neutralizing antibody responses, the titers in the two compart-
ments were directly correlated (r  0.65; P  0.0001) (Fig. 5B).
In addition, the maximal cytotoxic potency (the maximal pro-
portion of target cells positive for GzB after incubation with
antibodies and effector cells) was directly correlated between
plasma and milk (r  0.60; P  0.0001) (Fig. 5C). In contrast,
there was no correlation between the ADCC response and the
milk virus load (r  0.27; P  0.14) (data not shown). Inter-
estingly, although all HIV-infected lactating mothers had
ADCC activity detected against HIV DU422.1 gp120 in plasma
and milk, only a portion of subjects had detectable plasma
neutralization, and no milk neutralization response was de-
tected against the virus. These discrepant results may indicate
some differences in the specificities of neutralization and
ADCC-mediating antibodies.
Neutralization and ADCC in milk correlate with HIV Env-
specific IgG responses. Based on our findings, the functional
anti-HIV Env antibodies in milk appear to be predominantly
IgG isotype. To further confirm this observation, we correlated
the functional antibody responses in milk with the milk IgG
and IgA HIV Env-binding responses (Fig. 6). There was a
strong correlation between HIV Env-specific IgG binding re-
sponses and tier 1 neutralization in milk (ConS gp140, r  0.62
and P  0.0001; 1086c gp140, r  0.56 and P  0.0001; DU123
gp140, r  0.53 and P  0.0003; ConC gp140, r  0.63 and P 
0.0001; Con6 gp120, r  0.71 and P  0.0001; ConC gp120, r 
0.59 and P  0.0001; and gp41, r  0.43 and P  0.0049) (Fig.
6A and data not shown). Interestingly, a weak but significant
correlation was observed between anti-ConC gp140 IgA anti-
bodies and neutralization (r  0.30; P  0.049), whereas there
was no correlation between neutralization and IgA response to
all other antigens (r  0.17 to 0.25; P  0.10 to 0.30) (Fig. 6B
and data not shown) (Fig. 6B). The correlation with anti-gp41
IgA antibodies was not determined, as only 10% of breast milk
had detectable IgA of this specificity.
Finally, ADCC titers in milk correlated with milk HIV Env-
specific IgG binding responses. Since the ADCC assay used
NK cells that do not express Fc
 receptors, we did not com-
pare ADCC and HIV Env-specific IgA responses. However,
there was a highly significant, robust direct correlation between
the concentration of IgG antibodies to consensus HIV Env
glycoproteins and ADCC titers in milk (ConS gp140, r  0.61
and P  0.0001; Con6 gp120, r  0.59 and P  0.0001) (Fig.
6C). Similarly, the magnitude of the IgG response to clade C
Env glycoproteins and ADCC activity in milk were strongly
correlated (1086c gp140, r  0.71 and P  0.0001; DU123
gp140, r  0.71 and P  0.0001; ConC gp140, r  0.70 and P 
0.0001; and ConC gp120, r  0.64 and P  0.0001) (Fig. 6C and
data not shown). Thus, IgG antibodies directed against HIV
Env glycoproteins appear to primarily contribute to the anti-
viral functional humoral immune responses of breast milk.
DISCUSSION
Maternal antibodies transferred to the infant during breast-
feeding are important for protection against pathogens en-
countered during the first months of life. Although HIV Env-
TABLE 2. IgA neutralization in plasma and breast milk
Subject Sample
Anti-ConS gp140




3902 Plasma 707 50 0.95
Breast milk 252 50 2.67
605 Plasma 13,331 23.76 0.79
Breast milk 1,394 50 0.6
8304 Plasma 93 50 20.47
Breast milk 1,641 50 12.5
8802 Plasma 26 50 1.11
Breast milk 828 50 0.67
1209 Plasma 5,785 8.79 0.49
Breast milk 1,417 19.62 0.51
9701 Plasma 6,371 50 2.01
Breast milk 646 50 1.92
b12 0.13 0.57
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specific antibodies are detected in breast milk of infected
mothers, their role in the prevention of infant HIV acquisition
is still unclear (5, 31, 64). As viruses resistant to neutralization
by maternal plasma have been associated with transmission
through breastfeeding (48), it is possible that the virus neutral-
ization activity of breast milk is important in protection against
postnatal infant HIV acquisition. In this study, we investigated
the magnitudes and breadths of HIV Env-binding IgG and IgA
responses in breast milk, as well as the HIV-specific functional
humoral responses of breast milk compared to those of
plasma. Our results indicate that low levels of neutralizing and
ADCC-mediating antibodies are present in the breast milk of
chronically HIV-infected lactating mothers. Furthermore,
breast milk responses parallel plasma responses, suggesting
that functional HIV-specific antibodies in breast milk are
mostly derived from the systemic compartment. This low level
of neutralization detected in breast milk may indicate that
nonneutralizing antibodies or innate immune factors are in-
volved in protecting infants from postnatal HIV acquisition.
However, we cannot exclude the potential benefit of inducing
high levels of potent neutralizing antibodies in breast milk by
maternal immunization.
Antibodies in breast milk are mainly in the form of sIgA, a
dimeric antibody containing the J chain peptide and the secre-
tory component (60). Breast milk contains at least 1 log unit
more IgA than IgG (36, 60), but a bias toward the IgG isotype
TABLE 3. Autologous neutralization titers in plasma and milk
Virus Origina
Titerb
Plasma Breast milk Uninfected breast
milk (3 SD)c6 wk 3 mo 6 mo 9 mo 12 mo 6 wk 3 mo 6 mo 9 mo 12 mo
3305.A7 Plasma 23 26 36 4 4 6 48
3305.A10 Plasma 35 104 124 4 4 5 51
3305.C4 Plasma 25 20 30 4 4 5 72
3305.E9 Plasma 20 30 23 4 4 4 53
3305.BMC1 BMS 20 26 20 4 4 4 26
3305.BMC9 BMS 26 20 38 4 4 4 42
3305.BMC11 BMS 27 32 22 4 4 4 25
3305.BMF4 BMS 20 30 20 4 4 5 85
3305.BMF6 BMS 30 36 30 4 4 6 66
SVA.MLV 20 20 27 4 4 4 51
3902.A7 Plasma 20 30 59 463 9 20 13 6 55
3902.B10 Plasma 20 20 20 138 13 20 6 7 64
3902.G3 Plasma 20 51 44 159 13 20 5 6 63
3902.G10 Plasma 22 35 27 66 11 20 5 4 25
3902.G12 Plasma 20 33 40 75 13 20 12 11 37
3902.BMD7 BMS 20 20 20 NA 4 20 6 5 53
3902.BME6 BMS 20 20 21 51 13 20 8 11 69
3902.BMG14 BMS 20 24 47 108 4 20 5 10 116
3902.BM.H9 BMS 20 20 39 26 4 20 4 4 10
SVA.MLV 20 25 20 20 4 20 4 4 51
4403.A18 Plasma 20 37 20 4 4 4 28
4403.D1 Plasma 20 20 20 4 4 4 34
4403.H2 Plasma 20 27 20 4 4 4 25
4403.H7 Plasma 20 23 20 4 4 4 32
4403.BMB6 BMS 20 22 28 4 4 4 22
4403.BMB10 BMS 23 91 30 4 4 4 22
4403.BMC5 BMS 20 41 25 4 4 4 15
4403.BMG1 BMS 20 22 22 4 4 4 31
SVA.MLV 20 21 20 4 4 4 51
0301.A8 Plasma 32 24 27 15 14 4 76
0301.D1 Plasma 25 30 50 16 15 12 24
0301.E8 Plasma 20 20 20 16 19 14 79
0301.E9 Plasma 31 21 27 18 22 17 97
0301.BMA2 BMS 36 22 45 14 13 5 26
0301.BMA6 BMS 29 22 24 19 17 4 68
0301.BMA12 BMS 50 56 83 29 43 31 163
SVA.MLV 20 20 20 13 4 4 51
4707.E1 Plasma 20 20 27 39 61 7 15 29 18 23 52
4707.G3 Plasma 32 21 22 23 26 16 16 29 12 19 45
4707.H8 Plasma 27 26 37 42 50 8 14 24 17 26 49
4707.BMF8 BMS 31 32 42 46 62 16 18 56 25 47 37
4707.BM H2 BMS 27 23 32 47 67 8 16 27 17 25 32
SVA.MLV 20 20 20 20 20 5 5 17 5 18 51
a BMS, breast milk sample.
b A sample was considered positive (shaded) if the ID50 was greater than 3 times the SVA-MLV background and greater than 3 standard deviations above the mean
of the HIV-negative control samples. All negative controls from plasma had ID50 values of 20.
c The mean ID50 of uninfected milk controls plus 3 standard deviations.
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of the antibody response to HIV Env glycoproteins has been
reported in breast milk and other mucosal sites (35, 49, 64).
Accordingly, in this study, although we detected HIV Env-
specific IgG antibodies in the breast milk of all the women, the
seroprevalence of HIV Env-specific IgA antibodies was vari-
able between HIV Env antigens, ranging from 10% to 73%
(Table 1). Furthermore, milk IgG responses directed against
gp120 and gp140 were significantly higher than the milk HIV
Env-specific IgA responses, despite the 10-fold-higher total
IgA than IgG content of breast milk. A similar lower magni-
tude of breast milk SIV Env-specific IgA than IgG responses
has also been reported in rhesus monkeys (45, 54). The weak
IgA response to HIV Env glycoproteins in breast milk con-
trasts with the milk IgA response against other pathogens. In
fact, antibodies against rotavirus (47) and respiratory syncytial
virus (15) in breast milk are predominantly of the IgA isotype.
While HIV-specific IgA responses are detected during acute
HIV infection (72), previous studies have also reported that
the systemic IgA response against HIV Env proteins in chron-
ically infected individuals is of low magnitude (30, 35). Iden-
tifying pathways for induction of potent HIV-1-specific muco-
sal IgA antibody responses may be critical for an effective HIV
transmission-blocking vaccine.
The role of mucosal HIV Env-specific IgA antibodies in
FIG. 5. ADCC titers are 2 log units lower in milk than in plasma, but the maximal cytotoxic potencies are similar between the two
compartments. (A) The ADCC titer in milk is 2 log units lower than that in plasma. (B) A strong correlation is observed between ADCC titers
in milk and plasma. (C) The maximal cytotoxic potency, measured by the maximal proportion of gp120-coated target cells positive for GzB activity,
is correlated between paired milk and plasma samples.
FIG. 6. The magnitude of HIV Env-binding IgG antibody responses correlate with neutralization and ADCC responses in breast milk.
(A) Direct correlation between the magnitudes of the HIV Env-binding IgG antibody responses and the neutralizing antibody responses in milk.
(B) The magnitudes of HIV Env-binding IgA antibody responses do not correlate with the neutralizing antibody response in milk. (C) Direct
correlation between the magnitudes of the HIV Env-binding IgG antibody responses and the ADCC titer in milk.
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protection against virus transmission is still unclear. Previous
studies have reported that IgA antibodies isolated from mu-
cosal secretions are able to neutralize HIV virions (38, 59, 70).
These observations were mainly based on studying heavily
HIV-exposed but persistently seronegative (HEPS) subjects (8,
10, 22). However, a recent cross-laboratory analysis reported
that HIV-Env specific IgA antibodies are rarely detected in the
cervicovaginal fluid of HEPS women (37). In this study, we
detected neutralization in only 1 out of 35 (3%) non-IgG
breast milk fractions (subject 1209). This sample also had one
of the most robust HIV Env-specific IgA binding responses. As
the ratio of the milk HIV Env-specific IgA to total IgA appears
to be lower than that of IgG, larger amounts of milk IgA than
IgG might be required to neutralize. Accordingly, the milk IgA
IC50 of subject 1209 was more than 1 log unit higher than the
IgG IC50.
Most previous reports of the neutralization potency of HIV-
specific mucosal IgA have used PBMCs as reporter cells. This
assay is highly variable and is dependent on the donor cells
used in each assay (46). Therefore, we chose to use the TZM-bl
pseudovirus neutralization assay, an assay that has emerged as
a standard assessment of neutralization in the HIV field (39).
However, this assay may not be sufficiently sensitive for detec-
tion of IgA neutralization. It might therefore be necessary to
assess neutralization by mucosal IgA in alternative cell lines to
truly establish its neutralization potency. Aside from neutral-
ization, sIgA could also mediate nonneutralizing effector func-
tions that may play protective roles in mucosal HIV-1 trans-
mission. For example, sIgA antibodies may aggregate virions
and inhibit their movement through mucous and epithelial
layers (23), and IgA antibodies have been demonstrated to
inhibit virus transcytosis (24). More studies of the function of
HIV Env-specific mucosal IgA are needed to determine if
these types of responses are required for blocking HIV acqui-
sition.
Although passive immunization with nonneutralizing
ADCC-mediating immune sera did not protect neonatal in-
fants from oral challenge with SIV (16), the removal of the Fc
portion of the broadly neutralizing antibody b12 significantly
impaired its in vivo protective function (21). Thus, Fc-mediated
antibody functions could act synergistically with neutralization
to confer protection. In this study, HIV-specific ADCC re-
sponses were detected in the breast milk of all HIV-infected
women. ADCC-mediating antibodies could potentially be im-
portant in preventing the establishment of HIV infection in the
infant gut following ingestion of cell-free or cell-associated
virions. The assay used in this study specifically measured IgG-
mediated ADCC. It is also possible that HIV-specific IgA
could mediate cytotoxicity through interaction with phagocytes
in breast milk and the infant gut. The development of an assay
to measure IgA-mediated ADCC may be important to explore
all potential anti-HIV functions of mucosal IgA.
Plasma cells secreting HIV-specific IgG antibodies can be
detected in breast milk (63), and differences in the specific
activity of IgG between milk and plasma have been described,
suggesting a compartmentalization of the IgG response in
breast milk (4). This difference was marked by lower anti-
gp160 and higher anti-gp120 responses in breast milk than in
plasma. In this study, the magnitude of the responses was
consistently lower in breast milk than in plasma for all the
antigens tested. Furthermore, there was a strong correlation in
the magnitude of both neutralizing and ADCC responses in
breast milk and plasma, suggesting that the majority of the
functional antibodies in milk are derived from plasma. More-
over, IgGs isolated from breast milk and plasma had similar
neutralization potencies (Fig. 4), further supporting the hy-
pothesis that the neutralization responses in milk are mainly
attributable to plasma-derived IgG. The similar neutralization
potencies of HIV-specific IgG in milk and plasma differ from
results in rhesus macaques, where breast milk IgG antibodies
were slightly less potent at neutralizing a laboratory-adapted
strain of SIV than plasma IgG (45). These discordant results
may indicate a difference in the transfer of IgG from plasma to
breast milk between humans and nonhuman primates.
The neutralization potency of breast milk was significantly
lower than that of plasma, and autologous neutralization was
not detected in the majority of the breast milk samples tested
in this study (Table 3). Furthermore, although more than half
of the breast milk samples neutralized a tier 1 HIV, tier 2 virus
neutralization was scarcely detected (Fig. 3). As breast milk
neutralizing antibodies appear to be mostly derived from
plasma, the lack of detection of autologous response in this
compartment may be due to the weak response observed in
plasma and the low total antibody content of breast milk.
Autologous neutralizing responses usually develop over sev-
eral months, and plasma samples do not typically neutralize
contemporaneous viruses (50, 67). The autologous viruses
were derived from milk or plasma collected 4 weeks after
delivery, and the samples used in the studies were collected up
to 12 months after delivery. Similarly, in rhesus monkeys,
breast milk samples collected 1 year after SIV inoculation were
not able to neutralize the inoculated virus, but they neutralized
laboratory-adapted strains of the virus (45). These results in-
dicate that the level of neutralizing antibodies present in breast
milk might not be sufficient for in vivo HIV virion inhibition.
The observation that HIV-specific functional antibody re-
sponses appear to be primarily derived from the plasma could
have important implications for the development of a vaccine
to prevent mother-to-child HIV transmission through breast-
feeding. Our results suggest that an efficient maternal vaccine
to prevent breast milk HIV transmission may only need to
induce strong systemic humoral responses that would translate
into potent breast milk humoral responses. Passive immuniza-
tion studies may help determine the magnitude of the systemic
responses required to achieve potent neutralization in breast
milk.
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